HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Paul Balderes Selected Research

IMC-EB10

2/2005Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.
8/2004Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Paul Balderes Research Topics

Disease

16Neoplasms (Cancer)
01/2015 - 01/2004
4Carcinogenesis
09/2014 - 01/2004
2Melanoma (Melanoma, Malignant)
09/2014 - 01/2007
2Neoplasm Metastasis (Metastasis)
02/2010 - 01/2007
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
02/2005 - 08/2004
1Stomach Neoplasms (Stomach Cancer)
08/2011
1Pathologic Neovascularization
11/2006
1Breast Neoplasms (Breast Cancer)
11/2006
1Pancreatic Neoplasms (Pancreatic Cancer)
09/2006
1Macular Degeneration (Age-Related Maculopathy)
06/2006
1Leukemia
08/2004

Drug/Important Bio-Agent (IBA)

6AntibodiesIBA
01/2015 - 01/2004
5Monoclonal AntibodiesIBA
01/2015 - 03/2005
5LigandsIBA
06/2009 - 01/2004
4Immunoglobulin G (IgG)IBA
01/2010 - 08/2004
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2015 - 06/2006
2RamucirumabIBA
08/2011 - 06/2006
2Neutralizing AntibodiesIBA
02/2010 - 08/2004
2Cytotoxins (Cytolysins)IBA
02/2010 - 11/2006
2Phosphotransferases (Kinase)IBA
02/2010 - 06/2006
2Cetuximab (Erbitux)FDA Link
01/2010 - 09/2006
2Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
06/2009 - 06/2007
2Proteins (Proteins, Gene)FDA Link
06/2009 - 01/2007
2Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
06/2009 - 03/2005
2Platelet-Derived Growth FactorIBA
06/2007 - 01/2007
2AntigensIBA
01/2007 - 01/2007
2Bispecific AntibodiesIBA
01/2007 - 05/2005
2Growth Factor ReceptorsIBA
01/2007 - 01/2004
2Mitogen-Activated Protein KinasesIBA
11/2006 - 09/2006
2ErbB Receptors (EGF Receptor)IBA
05/2005 - 01/2004
2Epidermal Growth Factor (EGF)IBA
05/2005 - 01/2004
2Somatomedin Receptors (Somatomedin Receptor)IBA
05/2005 - 01/2004
2Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
03/2005 - 08/2004
2IMC-EB10IBA
02/2005 - 08/2004
1Cisplatin (Platino)FDA LinkGeneric
09/2014
1Proto-Oncogene Proteins c-kit (Proto-Oncogene Protein c-kit)IBA
09/2014
1Dacarbazine (DIC)FDA LinkGeneric
09/2014
1Etoposide (VP 16)FDA LinkGeneric
09/2014
1Pharmaceutical PreparationsIBA
08/2011
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
08/2011
1CytokinesIBA
02/2010
1Transforming Growth Factor beta Receptors (TGF beta Receptors)IBA
02/2010
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
02/2010
1Transforming Growth Factor beta (TGF-beta)IBA
02/2010
1Angiogenesis InhibitorsIBA
06/2009
1Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
06/2009
1Becaplermin (PDGF-BB)FDA Link
06/2007
1Monophenol Monooxygenase (Tyrosinase)IBA
01/2007
1Fc Receptors (Fc Receptor)IBA
01/2007
1Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA
11/2006
1IMC-18F1IBA
11/2006
1Immunoglobulin Fab FragmentsIBA
06/2006
1EpitopesIBA
06/2005
1cadherin 5IBA
06/2005
1Biological ProductsIBA
05/2005
1Platelet-Derived Growth Factor alpha ReceptorIBA
03/2005
1EnzymesIBA
08/2004
1fms-Like Tyrosine Kinase 3IBA
08/2004
1Immunoglobulins (Immunoglobulin)IBA
08/2004
1ImmunosorbentsIBA
08/2004

Therapy/Procedure

2Therapeutics
01/2015 - 09/2014
2Drug Therapy (Chemotherapy)
09/2014 - 02/2010
1Injections
02/2005